Nivolumab in Lung Cancer Shows Unprecedented Survival Nivolumab in Lung Cancer Shows Unprecedented Survival

Another phase 3 study has shown a survival benefit for the immunotherapy nivolumab compared with chemotherapy with docetaxel. Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news